Research Analysts Offer Predictions for SYRS Q1 Earnings

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Syros Pharmaceuticals in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.70) per share for the quarter. HC Wainwright has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for Syros Pharmaceuticals’ current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Syros Pharmaceuticals’ Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.68) EPS and Q4 2025 earnings at ($0.69) EPS.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same period last year, the company earned ($1.35) earnings per share.

A number of other analysts also recently commented on the stock. JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday. TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday. StockNews.com cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Piper Sandler reiterated an “overweight” rating and set a $5.00 price target (down previously from $13.00) on shares of Syros Pharmaceuticals in a report on Tuesday, August 13th. Finally, Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, Syros Pharmaceuticals currently has an average rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Price Performance

Shares of NASDAQ SYRS opened at $0.26 on Friday. The firm has a 50-day simple moving average of $2.02 and a 200-day simple moving average of $3.79. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97. The stock has a market capitalization of $6.96 million, a price-to-earnings ratio of -0.09 and a beta of 1.59. Syros Pharmaceuticals has a 52 week low of $0.25 and a 52 week high of $8.17.

Insider Buying and Selling at Syros Pharmaceuticals

In related news, CEO Conley Chee purchased 50,000 shares of Syros Pharmaceuticals stock in a transaction dated Tuesday, September 10th. The shares were acquired at an average cost of $1.51 per share, with a total value of $75,500.00. Following the purchase, the chief executive officer now owns 72,504 shares of the company’s stock, valued at approximately $109,481.04. The trade was a 222.18 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Jason Haas acquired 45,344 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was bought at an average price of $1.68 per share, for a total transaction of $76,177.92. Following the completion of the acquisition, the chief financial officer now owns 124,552 shares in the company, valued at approximately $209,247.36. The trade was a 57.25 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 130,707 shares of company stock worth $206,491 over the last quarter. 12.26% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Syros Pharmaceuticals

Institutional investors have recently modified their holdings of the company. GSA Capital Partners LLP purchased a new position in Syros Pharmaceuticals during the 3rd quarter valued at about $34,000. Virtu Financial LLC acquired a new position in shares of Syros Pharmaceuticals in the first quarter valued at approximately $64,000. Acadian Asset Management LLC purchased a new stake in Syros Pharmaceuticals during the 1st quarter worth approximately $91,000. Certuity LLC purchased a new stake in Syros Pharmaceuticals during the 2nd quarter worth approximately $109,000. Finally, Kennedy Capital Management LLC acquired a new stake in Syros Pharmaceuticals during the 1st quarter worth approximately $2,166,000. 91.47% of the stock is owned by institutional investors and hedge funds.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.